LUNIRI will present scientific data at the ERA-EDTA meeting in Vienna: May 21, 2016. Session CME 9: Rheumatology for Nephrologists. Title of the talk: "The topoisomerase I inhibitor irinotecan as a new treatment option for lupus nephritis?", 13.15-16.30 HALL E
Berlin Marathon 2017
LUNIRI in the News
New scientific data published in Arthritis Research & Therapy
Cancelation of credit card payment
Scientific presentation at the 53rd ERA-EDTA congress in Vienna 2016
Scientific presentation at the ISN Nexus Meeting in Berlin
LUNIRI will present scientific data at the ISN Nexus meeting in Berlin at Saturday 16 April 2016 17.00-17.25 Melia Hotel, room Barcelona. Title of the talk:
Irinotecan, an upcoming treatment option for lupus nephritis?
Vote to help establish a new treatment for systemic lupus erythematosus.
Berlin radio will donate 50.000 Euro for non-profit organizations. And without funding LUNIRI will not survive after 2016. Therefore, vote for LUNIRI at https://50000.brf914.de/61F4S. Repeated voting one day after another is possible. If you don’t mind, forward this message to your friends and colleagues with SLE. Thanks for your support.
New Luniri Video online
New Luniri Video EULAR 2015
New experimental findings of LUNIRI were published in the journal Arthritis and Rheumatology
In the current publication we show that the topoisomerase I (topo I) inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor furamidine in combination efficiently suppress lupus nephritis. While inhibitors of topo I stabilize the complex of topo I and DNA, the enzyme TDP1 releases topo I from the stalled complex. One previously known consequence of topo I inhibition is the prevention of DNA relaxation; this effect can be reverted by addition of TDP1. We demonstrated that these effects correlate with the binding of anti-dsDNA antibodies which are believed to be the main pathogen in systemic lupus erythematosus (SLE). We conclude from these data that DNA relaxation is crucial in the development of SLE and furthermore, changes in DNA relaxation by topo I and TDP1 inhibitors can be applied as entire new targeted therapy for this disease (Keil A. et al. Arthritis Rheumatol. 2015 Mar 16. doi: 10.1002/art.39119).
Congratulations to Andreas for his first publication as first author! Thanks to the team!